Geisinger Health System reports its precision medicine project has enrolled over 250,000 participants and produced already medically actionable results to nearly 1,500 health system members. The MyCode study is an ambitious program from a leading integrated health system. The outcomes have implications for precision medicine.
The precision medicine project involves ongoing DNA sequencing and other health data generation now also available for 145,000 of the MyCode program enrollees. The information from this program and its collaborators is stored in a system wide biobank currently in use by researchers from Geisinger and their partners to develop advanced precision treatments.
MyCode Study Results
Findings from the study include genetic predispositions to 34 health conditions such as breast cancer, hypercholesterolemia and arrhythmia not to mention genetic links to cognitive disorders that may not be medically actionable.
MyCode Investigator Comments
Christa Martin, PhD, associate chief scientific officer and a principal investigator, reported, “There are a lot of genes that have medical actionability, like finding a change in a gene that causes breast cancer and doing more frequent mammograms as a result.” Additionally, Martin reported that some of the results of the study are not actionable but are importation pointing toward implications for patients.
David Ledbetter, a PhD and executive vice principal and chief scientific officer as well as principal investigator, reported, “Giving these patients a unifying medical explanation for their multiple, apparently unrelated learning behavioral and psychiatric conditions had a powerful impact on these patients and their family members.”
What is MyCode Program?
The Mycode Program has been set up to analyze the DNA of patient-participants who sign up. With such a large body of data, they hope to find ways to make healthcare better. Its leadership includes Dr. Ledbetter.
Geisinger is committed to making better health easier for the more than 1.5 million consumers it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 13 hospital campuses, a 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With 32,000 employees and 1,800 employed physicians, Geisinger boosts its hometown economies in Pennsylvania and New Jersey by billions of dollars annually.
Christa Martin, PhD, associate chief scientific officer and a principal investigator
David Ledbetter, PhD and executive vice principal and chief scientific officer